Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06461910 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Esophagogastric Junction Adenocarcinoma

Interventions

DRUG: Serplulimab
DRUG: thymalfasin
DRUG: Oxaliplatin
DRUG: Tegafur

Sponsor

Zekuan Xu